DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Dr - 2 Mikhail Kosiborod - 2 “ - 2 ” Kosiborod - 2 Sanjay Gupta - 2 Kosiborod - 2 ” - 2 Wegovy - 1
Top related locs:
Asia Europe North South America Kansas City , Missouri Atlanta Kansas Kansas City
Top related orgs:
CNN - 2 New England - 2 of Medicine - 2 CNN Health - 2 Novo Nordisk – - 1 US Food and Drug Administration - 1 FDA - 1 St - 1

Search resuls for: "Mikhail Kosiborod"


2 mentions found


☆ Weight-loss drug Wegovy offers benefits for people with diabetes and common form of heart failure, study finds
  + stars: | 2024-04-06 | by ( Jen Christensen | ) edition.cnn.com   time to read: +8 min
The study, published Saturday in the New England Journal of Medicine, showed how the drug helped people with Type 2 diabetes who also had one of the most common kind of heart failure, obesity-related heart failure with preserved ejection fraction. Obesity-related heart failure with preserved ejection fraction can severely limit a person’s ability to participate in the activities of daily life. Often, people with type 2 diabetes who have this kind of heart failure have a more severe form than those who don’t have diabetes. People with a more severe form of heart failure sometimes don’t respond as well to medication as those with less severe disease. One death in the Wegovy group and four in the placebo group were related to cardiovascular issues.
Persons: Wegovy, Ozempic, Dr, Mikhail Kosiborod, “, ” Kosiborod, Naveed Sattar, ” Sattar, Sanjay Gupta, Kosiborod, ” Organizations: CNN, New England, of Medicine, Novo Nordisk –, US Food and Drug Administration, FDA, St, University of Glasgow, Science Media, CNN Health, American College of Cardiology Locations: Asia, Europe, North, South America, Kansas City , Missouri, Atlanta
☆ Weight-loss drug Wegovy produces ‘largest benefit ever seen’ for patients with most common form of heart failure, trial finds
  + stars: | 2023-08-25 | by ( Meg Tirrell | ) edition.cnn.com   time to read: +5 min
There are 64 million people globally living with heart failure, Novo Nordisk said in a statement about the trial results. This type of heart failure accounts for more than half of all cases in the US and is increasing in prevalence, according to Kosiborod and his co-authors. He noted that 80% of patients with this kind of heart failure in the US have obesity or are characterized as overweight. Until recently, the main treatment options for people with this kind of heart failure were diuretics, sometimes called water pills, Kosiborod said. They’re also changing the way researchers think about obesity, and the results in heart failure contribute to that paradigm shift, Kosiborod said.
Persons: Mikhail Kosiborod, ” Kosiborod, Kosiborod, semaglutide, ”, “, Eli Lilly, Dr, Sanjay Gupta, They’re, “ It’s Organizations: CNN, drugmaker Novo Nordisk, New England, of Medicine, Saint, Kansas, European Society of Cardiology, Novo Nordisk, CNN Health Locations: Kansas, Kansas City, Amsterdam
0 next >>
Total: 2